Is generic xifaxan available february 2026?

When Can You Expect Generic Xifaxan?

The prescription medication Xifaxan, generic name rifaximin, is used to treat irritable bowel syndrome with diarrhea (IBS-D). Rifaximin is a antibiotic that works by stopping the growth of bacteria that causes IBS-D.

Why is Xifaxan still under patent?

The original patent for the medication expired in 2018, but the manufacturer, AstraZeneca, has various extensions and patents that delay generic versions until 2026, according to [1] DrugPatentWatch.com.1

What's happening in 2026?

In 2026, several generic versions of rifaximin are expected to hit the market, potentially reducing the cost of this medication[2]. According to recent patent news, February 2026 marks the last exclusivity date for AstraZeneca's rifaximin. This date signifies the point when the last patents expire, allowing other manufacturers to release their generic versions. However, the final approval date may vary depending on the FDA's review timeline and other regulatory factors.

What are the implications for patient access?

Generic medications are crucial for increasing patient access to affordable healthcare. In this case, the generic versions of rifaximin will allow more patients to access this treatment for IBS-D without the high costs associated with brand-name medications. Generic manufacturers will likely release their versions in February 2026, or shortly after.

Who are the players in the market?

AstraZeneca's rifaximin is currently the only brand version of rifaximin available in the market. Several generic versions are pending FDA approval, but it is uncertain which companies will ultimately win approval to market their versions.

Sources:
[1] DrugPatentWatch.com, Patent: US-D-794492: Rifaximin (AstraZeneca)
[2] Generic and Biosimilar Medications for IBS-D, IbisWorld.